^
    23h
    A Study of TACE Combined With Camrelizumab Plus Rivoceranib (Apatinib) in Patients With Incurable Hepatocellular Carcinoma (clinicaltrials.gov)
    P3, N=423, Active, not recruiting, Jiangsu HengRui Medicine Co., Ltd. | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    AiRuiKa (camrelizumab) • AiTan (rivoceranib)
    1d
    Preoperative IMRT With Concurrent Apatinib for Localised Extremity or Trunk Sarcoma （SPARE-02） (clinicaltrials.gov)
    P2, N=30, Completed, Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Recruiting --> Completed
    Trial completion
    |
    AiTan (rivoceranib)
    2d
    Apatinib triggers ferroptosis in gastric cancer via HDAC1/HIF1α/CA9 signaling axis. (PubMed, Anticancer Drugs)
    This study elucidates a novel HDAC1/HIF1α/CA9 axis through which Apatinib induces ferroptosis. Targeting this pathway offers translational potential for overcoming Apatinib resistance in GC therapy.
    Journal
    |
    HIF1A (Hypoxia inducible factor 1, alpha subunit) • CA9 (Carbonic anhydrase 9) • GPX4 (Glutathione Peroxidase 4) • ACSL4 (Acyl-CoA Synthetase Long Chain Family Member 4) • HDAC1 (Histone Deacetylase 1)
    |
    AiTan (rivoceranib)
    8d
    Neoadjuvant Immune Checkpoint Inhibition in MSI-H/dMMR Colorectal Cancer: A Systematic Review of Prospective Trials Evaluating Efficacy, Pathologic Response, and Surgical Outcomes. (PubMed, J Gastrointest Cancer)
    Neoadjuvant immune checkpoint inhibition demonstrates high pathological and clinical response rates in dMMR/MSI-H colorectal cancer, with organ preservation achievable in selected rectal cancer patients. Neoadjuvant immunotherapy may become an alternative to surgery as the primary treatment for MSI-H/dMMR colorectal cancer if long-term quality of life is superior and toxicity and cost are competitive with standard surgical approaches. However, longer follow-up, predictive biomarkers, and randomized comparisons with upfront surgery are required before its routine clinical use.
    Review • Journal • Checkpoint inhibition • MSi-H Biomarker • PD(L)-1 Biomarker • IO biomarker • MSI-H • dMMR
    |
    MSI (Microsatellite instability)
    |
    MSI-H/dMMR
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • AiRuiKa (camrelizumab) • AiTan (rivoceranib) • Jemperli (dostarlimab-gxly)
    9d
    Infusional FOLFOX Plus Camrelizumab and Apatinib vs HAIC-FOLFOX Plus Camrelizumab and Apatinib for Advanced HCC (clinicaltrials.gov)
    P3, N=262, Recruiting, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | N=192 --> 262 | Trial completion date: Jul 2027 --> Jul 2029 | Trial primary completion date: Jul 2026 --> Jul 2028
    Enrollment change • Trial completion date • Trial primary completion date
    |
    5-fluorouracil • AiRuiKa (camrelizumab) • AiTan (rivoceranib) • oxaliplatin • leucovorin calcium
    15d
    Fuzuloparib with or without apatinib in patients with HER2-negative metastatic breast cancer with germline BRCA1/2 mutations (FABULOUS): interim analysis of a multicentre, three-arm, open-label, randomised, phase 3 trial. (PubMed, Lancet Oncol)
    Fuzuloparib, either as monotherapy or in combination with apatinib, provided statistically significant improvements in progression-free survival compared with chemotherapy in patients with HER2-negative metastatic breast cancer with germline BRCA1/2 mutations, presenting as new treatment options.
    Clinical • P3 data • P3 data: top line • Journal • BRCA Biomarker • PARP Biomarker
    |
    HER-2 (Human epidermal growth factor receptor 2) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset)
    |
    HER-2 negative
    |
    AiTan (rivoceranib) • capecitabine • vinorelbine tartrate • AiRuiYi (fluzoparib)
    16d
    Chemotherapy Strategies and Their Efficacy for Mesenchymal Chondrosarcoma. (PubMed, Curr Oncol)
    Trabectedin demonstrates low disease control rate in translocation-related sarcomas, including few MCS cases. Anti-angiogenic tyrosine kinase inhibitors, such as apatinib and pazopanib, demonstrate activity in chondrosarcoma, but MCS-specific data are lacking. IDH1 inhibition benefits conventional subtypes rather than MCS. Early immunotherapy experience is limited, but pathway-directed strategies targeting BCL2 and PI3K-mTOR warrant evaluation.
    Review • Journal
    |
    IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • BCL2 (B-cell CLL/lymphoma 2) • HEY1 (Hes Related Family BHLH Transcription Factor With YRPW Motif 1) • NCOA2 (Nuclear Receptor Coactivator 2)
    |
    AiTan (rivoceranib) • pazopanib • Yondelis (trabectedin)
    18d
    Fuzuloparib with or without apatinib as maintenance therapy in newly diagnosed, advanced ovarian cancer (FZOCUS-1): A multicenter, randomized, double-blind, placebo-controlled phase 3 trial. (PubMed, CA Cancer J Clin)
    Although poly(adenosine diphosphate-ribose) polymerase inhibitors (PARPis) and bevacizumab were approved as first-line maintenance for advanced ovarian cancer (OC), evidence comparing this combination with PARPi monotherapy, especially in BRCA-mutated/homologous recombination-deficient (HRD) patients, is lacking. Adding apatinib to fuzuloparib did not prolong PFS among homologous recombination-deficient patients. There was a PFS benefit trend among homologous recombination-proficient patients who received combination therapy compared with those who received monotherapy.
    Clinical • P3 data • Journal • BRCA Biomarker • PARP Biomarker
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • HRD (Homologous Recombination Deficiency) • BRCA (Breast cancer early onset)
    |
    BRCA mutation
    |
    Avastin (bevacizumab) • AiTan (rivoceranib) • AiRuiYi (fluzoparib) • Airuituo (bevacizumab biosimilar)
    22d
    CLARITY-Gastric 01: AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2 (clinicaltrials.gov)
    P3, N=572, Recruiting, AstraZeneca | Trial completion date: Apr 2027 --> Sep 2026 | Trial primary completion date: Oct 2026 --> May 2026
    Trial completion date • Trial primary completion date
    |
    paclitaxel • docetaxel • AiTan (rivoceranib) • Cyramza (ramucirumab) • irinotecan • Lonsurf (trifluridine/tipiracil) • sonesitatug vedotin (AZD0901)
    23d
    Combination of Carilizumab, Apatinib, and Radiotherapy for Advanced Mucosal Melanoma (clinicaltrials.gov)
    P2, N=30, Not yet recruiting, The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
    New P2 trial
    |
    AiRuiKa (camrelizumab) • AiTan (rivoceranib)
    25d
    A Study to Evaluate Camrelizumab Plus Rivoceranib (Apatinib) Versus Camrelizumab as Adjuvant Therapy in Patients With Hepatocellular Carcinoma (HCC) at High Risk of Recurrence After Curative Resection or Ablation (clinicaltrials.gov)
    P2, N=251, Completed, Jiangsu HengRui Medicine Co., Ltd. | Active, not recruiting --> Completed
    Trial completion
    |
    AiRuiKa (camrelizumab) • AiTan (rivoceranib)
    25d
    GASTO-10107: Induction Immuno-chemotherapy and Concurrent Chemoradiotherapy With or Without Apatinib in Unresectable, Locally Advanced Esophageal Squamous Cell Carcinoma (clinicaltrials.gov)
    P2, N=170, Active, not recruiting, Sun Yat-sen University | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    cisplatin • Loqtorzi (toripalimab-tpzi) • AiTan (rivoceranib) • capecitabine • albumin-bound paclitaxel